Scroll Up
Scroll Down
Play Play Play Play
Unregistered User
Click here if this is not your Personal Edition
 
Contact Us | Free E-Mail Updates | Journals | Register a colleague
 
 
Migraine
 
   
 
SEARCH   
Doctor's Guide Free CME
Medline
Congress Resource Centre
 

 EXPLORE :
   Most Read News
 All News  All News
 All Webcasts / CME  All Webcasts / CME
 All Cases  All Cases
 Congress Resource Centre  Congress Resource Centre
 All Medical Resources  All Medical Resources
 Medical  My Personal Edition



Warning | Privacy

 

 
 Recent news - Migraine
    TopAbstracts in Migraine 11/19/2009 - (DGNews)
    Migraine and cardiovascular disease: systematic review and meta-analysis - (BMJ)
    TopAbstracts in Migraine 10/22/2009 - (DGNews)
    TopAbstracts in Migraine 09/24/2009 - (DGNews)
    Preventive Treatment With Topiramate May Reduce Menstrually Related Migraines: Presented at EFNS - (DGDispatch)

    News archive

     Recent webcasts/CME

      Webcasts/CME archive

       Recent cases - Migraine
        Triptans and Troponin: A Case Report
        Topiramate-Associated Acute Glaucoma in a Migraine Patient Receiving Concomitant Citalopram Therapy: A Case-Report
        Acute Bilateral Simultaneous Angle Closure Glaucoma After Topiramate Administration
        A Case of Intermittent Ataxia Associated with Migraine Headaches
        Pneumatized Superior Turbinate as a Cause of Headache

        Cases archive
          




        my personal edition > migraine > news
        divider

          E-Mail this DGReview to a colleague

        DGReview


        Ibuprofen Suspension Effective Treatment For Paediatric Migraine

        A DGReview of :"Children's Ibuprofen Suspension for the Acute Treatment of Pediatric Migraine."
        Headache

        11/07/2002
        By David Loshak


        Paediatric ibuprofen suspension at an over-the-counter dose of 7.5 mg/kg relieves acute childhood migraines and is well tolerated.

        Specialists in paediatric neurology in Norfolk, Virginia, United States, drew attention, however, to a "striking difference" in response rates between the sexes. Boys responded at a statistically significant rate, the specialists said and because of a very high placebo responder rate, the girls did not.

        The specialists noted that migraine occurs in 4 percent of young children. There was little controlled clinical research in the treatment of childhood migraine and there were no approved drugs in the US for its treatment in children aged 12 years or younger.

        To assess the efficacy and tolerability of a single over-the-counter children's ibuprofen suspension 7.5 mg/kg versus placebo for the acute treatment of one attack of migraine, the specialists conducted a prospective, double-blind, placebo-controlled, parallel group, randomised study of children aged 6-12 years.

        There were two measures of efficacy. The first was headache severity based on a four point scale (severe, moderate, mild and no headache) at 30, 60, 90, 120, 180 and 240 minutes post-dose. The second was nausea, vomiting, photophobia and phonophobia at 120 minutes.

        The primary endpoint of the study was the cumulative percentage of responders (severe or moderate headache reduced to mild or none) by 120 minutes.

        Secondary endpoints were headache recurrence within 4 to 24 hours and any need for rescue medication within four hours.

        Of 138 children enrolled in the study, 84 were treated and completed diaries. Of these, 45 received ibuprofen and 39 received placebo. The two groups were demographically, diagnostically and clinically comparable.

        Nausea was eliminated in 60 percent of the children given ibuprofen compared with 39 percent of those given placebo - a statistically significant difference.

        Vomiting, photophobia and phonophobia fell marginally but not significantly at two hours.
        Headache 2002; 42(8):780-786. "Children's Ibuprofen Suspension for the Acute Treatment of Pediatric Migraine."

        E-Mail this DGReview to a colleague   To print, use this version






        All contents Copyright (c) 1995-2009 Doctor's Guide Publishing Limited. All rights reserved.



        The NTK initiative. Physicians helping physicians identify Need-To-Know science
           Feedback
        Please rate this article: Strongly DISAGREE...Strongly AGREE NTK logo
        Question 1 - Physicians need to become aware of this information as soon as possible. Question 2 - This information is likely to have an impact on the way physicians practice medicine.
        1
        2
        3
        4
        5
        6
        7
        Send